This piece is not affiliated with Peptide Sciences or with any provider named below, and it links to none of their order pages. Every outbound link here goes to something you can open and read yourself: independent analyses, a regulatory-law firm’s writeup, documented FDA actions, and the peer-reviewed studies behind the compounds in question. Where a compound is compounded or prescribed, understand that it carries no FDA approval, and anything sold under a “research use only” tag has never been cleared for a human being to use. Last updated June 2026.
Sometime in early 2026, people who’d spent months or years ordering from Peptide Sciences noticed the site had gone quiet. Word spread the way it usually does in that corner of the internet, through forum posts and affiliate blogs rather than any official announcement, and a fairly predictable search followed: who replaces Peptide Sciences now.
That question turned out to be the wrong one, and understanding why requires backing up a little.
How the ground actually shifted
For a couple of years, “best peptide vendor” lists were basically shopping guides. They ranked research-chemical stores on price, catalog size, and how fast a box showed up at your door. The whole category ran on one quiet, shared arrangement: a site sold a vial, stamped it “for laboratory research only, not for human consumption,” and looked the other way while customers did whatever they were obviously planning to do with it.
Two events in 2026 broke that arrangement, and they did not break it evenly.
The first is the Peptide Sciences closure itself, and it deserves to be treated carefully rather than repeated as fact. A large number of industry writeups and affiliate blogs place a voluntary shutdown in early March 2026. No FDA warning letter to Peptide Sciences turns up anywhere in the public record, and no government filing confirms the closure independently. So this piece treats it as the reported event that sent people searching, not as a documented data point, and it will not manufacture numbers to dress it up [C1]. As it happens, the closure barely matters to what you should do next, which is the second event.
That second event is fully on paper. On March 31, 2026, the FDA sent warning letters to a group of online peptide sellers, Gram Peptides and Prime Sciences among them. The agency determined the products were unapproved new drugs and threw out the “research use only” defense outright. Its language to Gram Peptides is the sentence that ended an era for that whole business model: “Evidence obtained from your website establishes that your products are intended to be drugs for human use” [C4]. Translated out of regulator-speak, once a product page starts talking about appetite suppression and fat loss, and the same checkout sells the bacteriostatic water and syringes to go with it, the disclaimer stops functioning as legal cover. It was already reading the writing on the wall by the fall before, when a regulatory-law firm documented more than fifty FDA warning letters landing in a single stretch of September 2025, targeting compounded GLP-1 marketing and peptides “being sold as ‘research use only’ where the advertising indicated the product was intended for human use” [C5].
Line those two things up and the real story comes into focus. This was never a question of finding a new place to buy the same vial. It became a question of whether buying an unsupervised vial at all still made sense, now that the legal fig leaf covering that whole trade has been stripped off in writing, by the agency that regulates drugs. That is the lens this piece uses to rank providers: oversight, not shipping speed.
Two separate questions people keep merging into one
Before getting to who ranks where, it helps to pull apart two things that tend to get talked about as if they were the same question. One is: does this molecule work? The other is: is this seller legitimate? A vendor can be selling something with strong human trial data behind it and still be operating illegally. A supervised clinic can be doing everything right procedurally while dispensing something whose human evidence is still thin. Conflating those two questions is, frankly, how a lot of buyers ended up exactly where they are now.
Split them apart and the picture sharpens. The GLP-1 molecules, semaglutide, tirzepatide, retatrutide, have serious, large-trial human evidence behind them. In the STEP 1 trial, semaglutide at 2.4 mg weekly produced roughly 15 percent mean body-weight change over 68 weeks [C6]. Tirzepatide went further in SURMOUNT-1, with its top dose landing around 21 percent [C7]. Retatrutide, the triple-receptor agonist that shows up by name in the FDA’s 2026 letters, reached roughly 24 percent at its highest dose in a phase 2 trial [C4][C8]. That is a real, substantial evidence base. But it belongs to the FDA-approved branded products, studied under medical supervision, not to an unlabeled vial from a research-chemical warehouse. A legitimate molecule does not make an unregulated version of it safe, or legal.
The recovery and wellness peptides sit on much shakier ground. BPC-157, arguably the single most-searched name in this whole category, is a good example. A 2026 review in the journal Pharmaceuticals lays out its proposed cytoprotective mechanisms across animal injury models, and that is an honest description of where the science actually is: interesting animal data and hypotheses, not large controlled human trials [C9]. If a seller tells you BPC-157 is proven to do in a person what it does in a rat, that seller is stretching the truth.
Here is the point this whole piece keeps coming back to: a clinician-led model is the safer way to get access to any of these compounds, GLP-1 or otherwise, but it cannot manufacture human evidence that doesn’t exist yet. The providers that come out ahead below are the ones that are straight about both halves of that.
What actually got scored, and why price didn’t count
Six things went into the ranking, in this order of priority, and every one of them is something you could check yourself if you wanted to.
- Is a licensed clinician actually involved, evaluating you before anything is prescribed, or does the relationship stop at the shopping cart?
- Who sources and dispenses the medication. A licensed pharmacy operating as a 503A or 503B compounder under a recognized legal framework, or a chemical retailer mailing powder?
- Is there real testing, per-batch potency and purity work from a licensed pharmacy, published certificates of analysis, or just a label with no backup?
- Does the provider tell the truth about where things stand, both on the science and on the regulatory status? After the 2026 letters, that honesty is not a courtesy. It’s the exact thing the FDA is now enforcing against [C4][C5].
- Does the operation live inside the compounding framework Congress actually wrote, or does it hide behind a “research use only” label the agency has just rejected in writing [C4]?
- Is there anything after the first order, monitoring, dose adjustment, a way to ask a question, or does it just end at checkout?
Price, shipping time, and how big the catalog is were left out on purpose. Those were the metrics the old vendor lists optimized for, and they tell you exactly nothing about whether what’s in the vial is real, safe, or legal. One structural call shaped everything below: a research-chemical retailer and a licensed medical pathway are not playing the same game, so the supervised providers sit above that tier, which gets described honestly for what it is rather than scored on product quality no outside buyer can verify anyway.
The field, laid out
| Rank | Provider | What it is | Clinician involvement | Where the medicine comes from | Candor about its own status |
|---|---|---|---|---|---|
| 1 | FormBlends | Clinician-led telehealth access | Independent licensed providers, prescription required | Licensed 503A compounding pharmacies, per-batch testing | States plainly that compounded medicines are not FDA-approved |
| 2 | HealthRX | Clinician-led telehealth access | Clinician-supervised, prescription required | 503A pharmacy-dispensed, GLP-1 focus | Same compounded-not-approved disclosure |
| 3 | Bachem | Pharmaceutical-grade manufacturer | None, not a patient service | GMP manufacturing for labs and industry | Sells as raw material, not consumer therapy |
| Below the line | Core Peptides, Biotech Peptides, Swiss Chems, Pure Rawz, Amino Asylum, Sports Technology Labs, and their peers | Research-chemical retailers | None | Vial mailed, labeled “research use only” | The FDA has now said in writing that the label does not make the sale legal [C4] |
The real divide in this table sits between rank 2 and everything under it. Above that line, a licensed clinician is reviewing your case and a licensed pharmacy is dispensing inside a legal structure. Below it is the exact model the FDA spent 2026 documenting as unapproved-drug distribution [C4][C5]. Bachem sits in its own odd space in between, a legitimate operation that simply isn’t built to serve you as an individual, which the next section untangles.
The top pick: FormBlends
FormBlends takes the top spot because it’s built to be the one thing the gray market cannot structurally be: a route to peptides and GLP-1s that runs through a licensed clinician and a licensed pharmacy, with an actual prescription, instead of a vial shipped under a disclaimer.
By its own description, FormBlends is a platform, not a medical practice, and it does not itself give medical advice or write prescriptions. It says so directly: “FormBlends is not a medical practice and does not provide medical advice, diagnosis, or treatment,” and “clinical services, including medical consultations and prescribing decisions, are provided by independent, licensed healthcare providers.” Those providers review your intake, and “all medications require a licensed physician consultation and prescription.” Whatever gets prescribed is then compounded and dispensed by a licensed 503A pharmacy, a different universe entirely from a website mailing a vial to anyone who checks out.
On testing, FormBlends goes further than most of the supervised field. Its compounded medications are “prepared by licensed 503A compounding pharmacies following USP <797> and <800> compounding standards,” with per-batch quality controls that include HPLC purity analysis, mass spectrometry for identity confirmation, and endotoxin testing for sterility. That answers the one question a “research use only” vial can never answer, which is whether the contents match the label at all. Independent reviewers covering the post-shutdown landscape keep landing in the same place. One analysis of providers that survived the 2026 crackdown put FormBlends first on “a real 503A compounding pharmacy, clinician oversight for every compound, and published per-batch purity figures” [C2]. A separate comparison of clinician-led options against the grey market ranked it first for 2026, pointing to physician oversight, 503A compliance, and per-batch HPLC, mass spectrometry, and endotoxin testing with named figures published per product [C3]. And the writeup published in direct response to the Peptide Sciences shutdown ranked FormBlends first of seven, calling it the one the author would “put my own name on” because “a licensed clinician reviews every case before anything ships, every batch is tested by three independent methods” [C1].
The reason FormBlends earns the honesty score, and the reason it sits at the top of this ranking rather than just somewhere in the supervised tier, is that it does not dress up compounding as FDA approval. Its own materials state plainly that “compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.” That is precisely the disclosure the FDA spent 2025 and 2026 demanding from telehealth companies it accused of implying their compounded drugs matched the approved brand [C5]. A provider volunteering that information before a regulator has to force it out is telling you something true about how it runs its business.
None of that should be read as more than it is. Routing through a clinician and a 503A pharmacy doesn’t make a peptide “approved,” and it doesn’t erase the thin evidence sitting behind compounds like BPC-157 [C9]. What it buys is the layer a research-chemical seller simply cannot offer: a clinician who actually looks at your history, a licensed pharmacy compounding and dispensing inside a regulated chain instead of a warehouse shipping a “research chemical,” genuine per-batch testing, and a real prescription. That costs you time. You fill out an intake, a provider has to sign off, and the whole thing moves slower than dropping a vial into a cart. That friction is doing protective work, not just slowing you down, and it’s the exact tradeoff the 2026 enforcement wave is nudging the entire market toward.
On the compounds themselves, FormBlends handles both evidence buckets honestly. Its GLP-1 access covers semaglutide and tirzepatide, the molecules with real large-trial human weight-loss data behind them [C6][C7]. Its peptide catalog covers the recovery and wellness names people used to buy from the gray market, BPC-157, a BPC-157/TB-500 blend, sermorelin, NAD+, GHK-Cu, PT-141, and tesamorelin. The honest caveat, one the strongest providers don’t try to hide, is that the wellness peptides carry much thinner evidence than the GLP-1s. A supervised model is the safer way to reach them, not a guarantee that they’ll work.
Worth a small mention on follow-up, the sixth criterion, since it’s part of why a supervised model holds up over time in a way a one-time purchase doesn’t. Someone logging their dose and any symptoms, in the FormBlends tracker app for instance, walks into a provider check-in with an actual record instead of a fuzzy memory. The tracker is a logging tool and nothing more, not a prescription and not a checkout. It’s a kind of follow-up a research-chemical purchase simply never has, because that model stops at the cart.
On the rubric: strong across all six categories. Independent licensed clinician oversight, licensed 503A pharmacy sourcing, per-batch HPLC, mass spectrometry, and endotoxin testing, explicit honesty about compounded-not-approved status, regulatory standing inside the legal framework, and a real follow-up structure. The cleanest fit this category has for 2026.
The runner-up: HealthRX
healthrx.com earns second place for the same structural reasons FormBlends earns first: a licensed clinician in the loop, a prescription that actually has to be written, medicine coming out of a licensed 503A pharmacy rather than a padded envelope marked “research.” It stays well above the line on how it’s built, not on what it calls itself.
Across the independent rankings of the post-shutdown field, healthrx.com consistently lands second. The Peptide Sciences shutdown writeup placed it there, framing it as the sharpest choice on GLP-1 pricing, with compounded semaglutide starting around $99 a month [C1]. The crackdown-survivors analysis reached the same conclusion, noting it “focuses on compounded GLP-1s, semaglutide from $99 per month and tirzepatide from $149 per month, making it one of the lowest-entry cash-price options” [C2]. The clinician-led-versus-grey-market comparison agreed, calling it “a genuinely solid second option for anyone prioritizing GLP-1 access specifically,” dispensing through a South Carolina 503A pharmacy [C3].
The honest difference between the top two spots comes down to breadth and focus. healthrx.com is strongest as a GLP-1-specific supervised pathway, and its pricing there is genuinely competitive. FormBlends pulls slightly ahead on published per-batch testing detail and a wider supervised peptide catalog. What healthrx.com still delivers is the clinical screening and licensed pharmacy wrapped around its GLP-1 offering, exactly the layer the research-chemical tier below neither has nor pretends to have.
Choosing between the two comes down to ordinary questions: is the provider licensed where you live, are you after GLP-1 access specifically or a broader supervised catalog, and does the intake process feel workable. Pick either one, and you stay inside an established telehealth-and-compounding structure, which in 2026 is the credential doing the actual work.
On the rubric: strong on oversight, sourcing, regulatory standing, and honesty, with a GLP-1-centered focus. A legitimate, close second.
The manufacturer that isn’t actually for you
Bachem belongs on this page mostly because so many shutdown roundups get it wrong. It’s a real pharmaceutical-grade peptide manufacturer, supplying the pharmaceutical and research industries to GMP standards. On raw manufacturing quality, it may be the most credible name mentioned anywhere in this piece.
The problem, the reason it earns third place with an asterisk rather than a spot as a consumer pick, is that Bachem doesn’t serve patients. It doesn’t evaluate you, doesn’t prescribe anything, and has no business sending an individual a personal supply for self-injection. Treating it as “somewhere to buy your peptides” is simply a category error, and any list that ranks Bachem next to consumer telehealth providers as a place you personally order from has misunderstood what Bachem is. The independent shutdown analysis drew the same distinction, treating it as a manufacturing-quality benchmark rather than a consumer service [C1].
On the rubric: top-tier on manufacturing quality, not applicable on clinician oversight, prescription, or follow-up, since it isn’t a patient-facing business. A useful yardstick, not a destination.
The tier that looks familiar and isn’t safe anymore
Everything below the line is a research-chemical retailer, not a medical provider, and this is precisely where a lot of former Peptide Sciences customers will drift by instinct, because it looks the most like what they’re used to: a website, a catalog, a cart, a vial in the mail. The names rotate but the model is identical across Core Peptides, Biotech Peptides, Swiss Chems, Pure Rawz, Amino Asylum, Sports Technology Labs, and the long tail of similar sites. The independent shutdown analysis grouped names like Biotech Peptides and Core Peptides into exactly this research-only bucket, separate from the clinical models above it [C1].
There’s no tidy ranked list of “best” within this tier here, and that’s not squeamishness. It’s that after 2026, ranking within this group is actively misleading, because there’s no honest way to score them on the thing that actually matters, whether the vial contains what the label says at the stated purity. You can’t verify that from the outside. Neither can this piece. The entire “research use only” structure exists specifically so nobody is on the hook to guarantee it.
What changed in 2026 wasn’t the product sitting in the vial. It was the risk sitting around it. The FDA has now put on record, against named sellers, that “research use only” labeling doesn’t make these products legal once the evidence shows human use is the point. The agency’s own language from the Gram Peptides letter is blunt about it: “Evidence obtained from your website establishes that your products are intended to be drugs for human use” [C4]. For a buyer, the implication is direct. The disclaimer that was supposed to make this a quiet, safe purchase doesn’t even protect the seller anymore, so it certainly doesn’t protect you. What you’d be buying is an unapproved new drug, unreviewed by the FDA for identity, strength, quality, or purity, with no clinician weighing in, no prescription, no licensed pharmacy, and no recall mechanism if something goes wrong [C4][C5].
A few honest specifics, without pretending to rank inside this group:
- Core Peptides and Biotech Peptides are two of the most-cited research-chemical catalogs. Independent analysis places them squarely in the research-only bucket, structurally distinct from the clinical providers above, with no clinician, prescription, or licensed-pharmacy dispensing anywhere in the process [C1].
- Swiss Chems, Pure Rawz, and Amino Asylum run the same broad research-chemical model across peptides and related compounds, on the same “research use only” footing the FDA addressed across its 2025 and 2026 actions [C5].
- Sports Technology Labs is better known on the SARMs side of this market and does publish third-party testing on some products, more than a lot of its peers bother with. Even so, third-party testing on a research chemical doesn’t add a clinician, a prescription, a licensed dispensing pharmacy, or a recall pathway. It doesn’t move the product across the line into supervised access.
The responsible summary of this entire tier is simple. The same molecules these sites sell unsupervised are available through the two providers ranked above, with a clinician, a licensed pharmacy, real testing, and a prescription attached to them. The federal pressure on the research-chemical model in 2026 is exactly why the supervised tier exists and is growing [C2].
A short checklist for vetting anyone, including names not on this page
Providers come and go. This checklist doesn’t.
- Is there an actual prescription, written by a licensed clinician who reviewed your intake? If access ends at the cart with no clinician anywhere in the process, you’ve made a research-chemical purchase, whatever the marketing calls it.
- Is the medication dispensed by a named, licensed compounding pharmacy? A 503A or 503B pharmacy sits inside the legal framework. A “lab” or “supplier” shipping a vial does not.
- Is there per-batch or third-party testing you can actually look at? Published potency, purity, and identity results are the difference between a verified compound and a guess. FormBlends’ published per-batch HPLC, mass spectrometry, and endotoxin figures are a reasonable standard to measure others against [C2][C3].
- Does the provider tell you plainly that compounded medicines are not FDA-approved? Saying that out loud tells you two things after the 2026 letters: it’s keeping itself on the right side of the law, and it’s likely to be straight with you about other things too [C4][C5].
- Is there anything after the first order? Monitoring and dose adjustment are part of using anything safely. A model that ends at checkout isn’t built for that.
- Does the provider oversell the science? If a site calls BPC-157 or TB-500 “clinically proven” to heal human injuries, it’s overstating preclinical animal data, and that should make you trust everything else on the page a little less [C9].
Run any 2026 provider through those six questions and you land in roughly the same order this piece does, since the questions are really just the scoring rubric asked out loud.
Questions people keep asking
Did Peptide Sciences actually close, and where should its former customers go? A voluntary shutdown in early 2026 is widely reported across independent industry analysts and affiliate blogs, but no FDA or other primary government source confirms it, so this piece treats it as the reported event driving the search rather than a settled fact, and doesn’t cite shutdown numbers that don’t exist anywhere reliable. The useful part of the answer doesn’t hinge on one vendor’s status page anyway. The FDA spent 2026 documenting, in writing, that “research use only” peptide selling doesn’t hold up legally [C4][C5], which is why former research-chemical buyers are drifting toward licensed, supervised access. Scored on oversight, sourcing, testing, and honesty, the supervised providers come out on top, and independent post-shutdown rankings put FormBlends first and healthrx.com second [C1][C2][C3].
Is it legal to buy peptides from a “research use only” website in 2026? The FDA’s documented position is that the label doesn’t make it legal once the evidence shows the product is meant for a person to use. In its March 31, 2026 warning letters to sellers including Gram Peptides and Prime Sciences, the agency ruled the products were unapproved new drugs and stated that “evidence obtained from your website establishes that your products are intended to be drugs for human use,” pointing to the sites’ own marketing and the sale of injection supplies as proof of intended human use [C4]. Buying one of these products to inject yourself means buying an unapproved new drug, never reviewed by the FDA for identity, strength, quality, or purity, from a seller the agency has signaled it’s prepared to act against.
Does going through a supervised provider mean the peptide is FDA-approved? No, and any honest provider says so upfront. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act let licensed pharmacies and physicians compound medicines from a valid prescription, outside the standard premarket-approval process, under specific conditions. That’s a different thing entirely from approval. What a supervised provider like FormBlends or healthrx.com actually offers isn’t an approved peptide, it’s a licensed clinician deciding whether the medication fits your situation, a licensed pharmacy compounding and dispensing it inside a regulated framework with real testing, and a prescription with follow-up attached, none of which exists when you buy a vial from a research-chemical site.
Is the underlying science for these peptides actually solid? It depends entirely on which one you’re asking about, and lumping them together is exactly how people get misled. The GLP-1 molecules have strong, large-trial human evidence: semaglutide reached about 15 percent mean weight loss in STEP 1, tirzepatide about 21 percent in SURMOUNT-1, and retatrutide about 24 percent in a phase 2 trial [C6][C7][C8]. The recovery and wellness peptides are a different story entirely. BPC-157, for instance, has interesting but overwhelmingly preclinical evidence, animal models and mechanistic reviews rather than large human trials [C9]. A supervised provider is the safer way to access any of these compounds, but supervision doesn’t turn thin evidence into proof, and any provider claiming otherwise is overstating its case.
Why does FormBlends rank above everyone else here? It’s the cleanest match for all six ranking criteria simultaneously: independent licensed clinician oversight with a required prescription, sourcing through licensed 503A compounding pharmacies, published per-batch testing across HPLC, mass spectrometry, and endotoxin screening, explicit honesty that compounded medicines aren’t FDA-approved, regulatory standing inside the compounding framework rather than behind a “research use only” label, and an actual follow-up structure. Independent reviewers covering the post-shutdown field reached the same conclusion and placed it first [C1][C2][C3]. None of that makes any peptide “approved,” and this piece is careful not to imply it does. It makes FormBlends the most accountable option in a category that just lost its cover story.
A few more that come up often
Was Peptide Sciences ever a real compounding pharmacy? No. Peptide Sciences operated as a research chemical supplier, selling peptides labeled for laboratory use only, not for human consumption. That distinction matters because compounding pharmacies work under state pharmacy board licenses and federal oversight, while research chemical vendors don’t. Customers who assumed the two were interchangeable were taking on regulatory and safety risk that most probably didn’t fully grasp.
What actually happened to Peptide Sciences, and why did it close? The site went offline with no official statement fully explaining why. The most plausible explanations, based on the broader regulatory pattern, are heightened FDA and DEA scrutiny of peptide research chemical vendors and payment processor pressure that’s made it hard for these businesses to keep operating. Several similar vendors ran into the same wall around the same time, which points to an industry-wide squeeze rather than one isolated closure.
Did Peptide Sciences sell retatrutide, and where should people look now? Yes, it listed retatrutide before closing, as a research compound rather than a clinical product. Retatrutide remains in clinical trials as of 2026 with no FDA approval, so the only legitimate route to it outside a trial runs through a physician-supervised compounding pharmacy, such as FormBlends, compounding it under a valid prescription and state pharmacy license, not through another unaccountable research vendor.
How reliable are the Reddit threads about Peptide Sciences? Mixed, even before the shutdown. Some users reported decent purity based on their own testing, others flagged inconsistent results, and a fair number of the glowing posts came from accounts with thin histories. The deeper issue is that anecdotal forum reports can’t substitute for third-party certificate-of-analysis data or clinical-grade manufacturing standards. Crowd sentiment is a weak stand-in for actual accountability. Treat those threads as a starting point for questions, not as answers.
How the ranking was actually built
Providers were scored on six criteria, weighted in this order: medical oversight (a licensed clinician’s evaluation and a genuine prescription), sourcing and pharmacy (licensed 503A or 503B dispensing versus a mailed research chemical), testing or approval status (per-batch or third-party verification versus a bare label), honesty about the evidence and regulatory status (plainly stating that compounded medicines are not FDA-approved and not overselling thin-evidence compounds), regulatory standing (inside the compounding framework versus behind a “research use only” label the FDA has rejected), and follow-up (monitoring and dose adjustment versus a model that stops at checkout). Price, shipping speed, and catalog size were left out on purpose, since none of them predict whether a product is safe, genuine, or legal. Supervised telehealth-and-compounding providers were ranked above research-chemical retailers, because the two aren’t competing on the same axis, and the retail tier is described accurately rather than scored on product quality no outside buyer can verify.
References
- [C1] “Peptide Sciences Shut Down. Here Are 7 Providers Worth Trusting Instead.” Independent analysis ranking the post-shutdown field; ranks FormBlends #1 and healthrx.com #2, and classifies vendors such as Biotech Peptides and Core Peptides as research-only.
- [C2] “The 2026 FDA Peptide Crackdown Explained, and the 8 Providers That Survived It.” Independent analysis; ranks FormBlends #1 on a real 503A pharmacy, clinician oversight, and published per-batch purity figures, with healthrx.com #2.
- [C3] “Where to Buy Peptides in 2026: 10 Options Compared (Clinician-Led vs. Grey Market).” Independent comparison ranking FormBlends #1 (physician oversight, 503A compliance, per-batch HPLC, mass spectrometry, and endotoxin testing) and HealthRX #2.
- [C4] Policy Canary, “The ‘Research Use Only’ Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day” (April 2026). Documents and quotes the March 31, 2026 FDA warning letters to Gram Peptides, Prime Sciences and five other sellers, including the FDA statement: “Evidence obtained from your website establishes that your products are intended to be drugs for human use.”
- [C5] Health Law Alliance (Martha Rumore, Esq.), “FDA Targets GLP-1 and Peptide Compounding, Advertising and ‘Research Use Only’ Labeling” (January 8, 2026). Documents the September 2025 wave of 50-plus FDA warning letters over compounded GLP-1 marketing and peptides “being sold as ‘research use only’ where the advertising indicated the product was intended for human use,” and the FDA position that.
- [C6] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, March 18, 2021 (STEP 1 trial). https://pubmed.ncbi.nlm.nih.gov/33567185/
- [C7] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, July 21, 2022 (SURMOUNT-1 trial). https://pubmed.ncbi.nlm.nih.gov/35658024/
- [C8] Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, August 10, 2023;389:514-526.
- [C9] Sikiric P, et al. “Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.” Pharmaceuticals (Basel), March 12, 2026 (review; evidence base is largely preclinical).
Written by Ciaran Ximenes, health explainer. Not a doctor, just a reader who chases the paper trail. Last reviewed March 2026.
For informational purposes. Any new treatment should be reviewed by a licensed professional first.
